In the last 7 days
Al Sandrock prunes his post-Biogen voyage with similar focus on ALS ENDPOINTS10:32 5-Aug-22
Speaker Program Compliance: Biotech Company Settles False Claims Act Allegations for $900 Million JD Supra15:35 4-Aug-22
BIIB September 23rd Options Begin Trading Nasdaq12:19 4-Aug-22
Biogen and Eisai share latest lecanemab results for the treatment of Alzheimer's disease PMLiVE07:57 4-Aug-22
Eisai Presents New Findings on Lecanemab's Investigational Subcutaneous Formulation and… JCN Newswire22:02 3-Aug-22
Alzheimer’s drug Aduhelm may fail to win nod in Korea Korea Biomedical Review21:17 3-Aug-22
Eisai Presents New Findings On Lecanemab’s Investigational Subcutaneous Formulation And Modeling Simulation Of APOE4… Biogen (Press Release)19:36 3-Aug-22
Roche gets busy at the deal table, wagering $190M upfront on off-the-shelf CAR-Ts and ex-Biogen … FierceBiotech09:59 3-Aug-22
$964 Billion Worldwide Biotechnology Industry to 2027 - Featuring Amgen, Biogen, Novartis and… Business Wire (Press Release)04:35 3-Aug-22
In the last month
Biogen's new SMA awareness campaign in Spain spotlights the 'invisible' caregivers ENDPOINTS15:18 1-Aug-22
Positive results for Biogen’s lupus drug published in NEJM PMLiVE07:54 1-Aug-22
Biogen deflects claims it misled shareholders about Aduhelm's success FiercePharma10:27 29-Jul-22
Biogen Denies Misleading Investors Over Alzheimer's Drug Law36021:31 28-Jul-22
Pushing Back on Kickbacks: $900 Million Settlement in Biotech False Claims Act Case National Law Review19:03 28-Jul-22
FDA Accepts New Drug Application for Tofersen as Treatment of SOD1-ALS Pharmacy Times16:58 28-Jul-22
Thursday’s Top Analyst Upgrades and Downgrades: Alphabet, Autodesk, Biogen, Chipotle Mexican… 24/7 Wall St.09:20 28-Jul-22
Biogen’s New Drug Application for first treatment of rare form of neurological disease accepted by FDA Labiotech09:06 28-Jul-22
The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus… GlobeNewswire (Press Release)07:35 28-Jul-22
Biogen Stock: Clinical Wins Support a Bullish Thesis TipRanks00:49 28-Jul-22
FDA Accepts Biogen’s New Drug Application with Priority Review for Tofersen for a Rare, Genetic Form of ALS Trial Site News19:39 27-Jul-22
FDA grants priority review for Biogen’s tofersen to treat ALS Pharmaceutical Technology10:47 27-Jul-22
FDA grants priority review to Biogen’s tofersen for genetic form of ALS PMLiVE07:49 27-Jul-22
Biogen ALS Drug Granted FDA Priority Review, Triggering Aduhelm Déjà Vu Scrip Pharma Intelligence17:56 26-Jul-22
FDA will consider Biogen’s ALS drug, despite mixed results in clinical trial Boston Globe17:52 26-Jul-22
FDA’s decision to review a Biogen ALS drug is met with skepticism and uncertainty on Wall Street STAT15:53 26-Jul-22
Biogen gets much-needed pipeline lift with speedy ALS drug review pharmaphorum13:45 26-Jul-22
Biogen wins FDA priority review for ALS therapy Biopharma Reporter12:39 26-Jul-22
Biogen watch out: Novartis' Tysabri biosim application could portend multiple sclerosis… FiercePharma12:32 26-Jul-22
Biogen/Ionis Scores NDA Nod for ALS Candidate BioSpace12:32 26-Jul-22
Key elements of influential Alzheimer’s study may have been fabricated, report says Boston Globe11:24 26-Jul-22
In another accelerated approval quest, Biogen will send its ALS drug to the FDA despite inconclusive data ENDPOINTS11:24 26-Jul-22
U.S. FDA accepts Biogen’s ALS therapy for review FX Empire11:11 26-Jul-22
FDA grants Priority Review to Biogen's ALS therapy MarketWatch10:23 26-Jul-22
Ever the optimist, Biogen secures FDA priority review for ALS drug that flunked phase 3 FierceBiotech10:12 26-Jul-22
Biogen's ALS Drug Will Get FDA Review. It's a Long Shot for the Stock. Barron's Online09:48 26-Jul-22
Pharmalittle: FDA will review Biogen ALS drug despite inconclusive results; Shkreli launches… STAT09:30 26-Jul-22
ALS Drug From Biogen Could Become First to Target Genetic Cause of Disease BNN Bloomberg09:17 26-Jul-22
U.S. FDA grants priority review to Biogen's ALS drug Reuters08:14 26-Jul-22
Biogen Gets FDA Priority Review of Tofersen in Rare Form of ALS >BIIB MarketWatch08:10 26-Jul-22
FDA agrees to review ALS treatment from Biogen, despite inconclusive clinical trial results STAT07:41 26-Jul-22
FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS GlobeNewswire (Press Release)07:32 26-Jul-22
Ionis announces that FDA accepts New Drug Application and grants Priority Review of tofersen… PR Newswire (Press Release)07:30 26-Jul-22
Novartis takes aim at MS blockbuster Tysabri in US and Europe pharmaphorum05:32 26-Jul-22
Novartis asks FDA to approve biosimilar for Biogen's top-selling MS drug BioPharma Dive18:34 25-Jul-22
BIIB vs. ILMN: Which Stock Should Value Investors Buy Now? Nasdaq13:04 25-Jul-22
Novartis generics arm files for MS biosimilar, challenging Biogen; Pluristem shortens name ENDPOINTS11:25 25-Jul-22
Multiple sclerosis: Biogen to settle claims it bribed doctors to prescribe drugs, with over $200m going to whistleblower British Medical Journal07:35 25-Jul-22
Biogen tops Q2 2022 earnings and revenue estimates Invezz02:28 24-Jul-22
Gainey McKenna & Egleston Investigates The Officers And Directors Of Biogen, Inc. (BIIB) GlobeNewswire (Press Release)15:14 22-Jul-22
After failed Alzheimer's launch, Biogen writes off the remaining value of its Aduhelm inventory FiercePharma13:08 22-Jul-22
Roche, Biogen temper Alzheimer’s expectations in Q2 calls. Will Lilly follow suit in August? FierceBiotech10:57 22-Jul-22
For accounting purposes, Biogen says its $223M inventory of Aduhelm is basically worthless ENDPOINTS14:57 21-Jul-22
Amicus Filings in Biogen v. Mylan Urge SCOTUS to Eliminate Uncertainty in Drafting Patents to Satisfy Written… IPWatchdog.com14:05 21-Jul-22
Biogen discloses $900M agreement in whistleblower kickback suit Compliance Week11:54 21-Jul-22
Biogen Quietly Resolves Whistleblower Case for $900M BioSpace10:21 21-Jul-22
Biogen sheds neuroscience drug programs amid uncertain future Boston Globe08:53 21-Jul-22
Investors Frown Despite Biogen’s Decent Q2 Results, Improved Outlook TipRanks02:21 21-Jul-22
Without An Alzheimer’s Blockbuster, Biogen Is A Ship Without A Growth Rudder Scrip Pharma Intelligence19:46 20-Jul-22
Biogen agrees to $900 million drug kickback settlement on eve of trial Reuters18:12 20-Jul-22
Health Care Down as Biogen, Merck Retreat -- Health Care Roundup MarketWatch17:22 20-Jul-22
Biogen To Pay $900M To Settle Kickback Claims On Trial's Eve Law36014:27 20-Jul-22
Biogen agrees to pay $900 million to settle whistleblower case alleging kickbacks and sham… STAT14:11 20-Jul-22
Biogen sets out plan for development of Alzheimer's drug Irish Examiner13:00 20-Jul-22
Biogen Inc. Agrees To Pay $900 Million To Resolve Whistleblower Claim Regarding Payment Of… PR Newswire (Press Release)12:46 20-Jul-22
With Aduhelm sidelined, Wall Street turns to Biogen's next Alzheimer's drug BioPharma Dive12:31 20-Jul-22
Biogen CEO Michel Vounatsos points to inherent risk in neuroscience as 3 programs cut FierceBiotech11:21 20-Jul-22
Biogen primes investors for a lecanemab data dredge Evaluate Group10:54 20-Jul-22
Biogen pays $900M to resolve whistleblower's MS kickback suit as competition drags on sales FiercePharma10:47 20-Jul-22
Biogen Axes Schizophrenia Program, Touts Potential of Next Alzheimer's Drug BioSpace10:10 20-Jul-22
Biogen posts solid quarter but pipeline slims ahead of key data for its second controversial Alzheimer's drug ENDPOINTS09:25 20-Jul-22
Biogen chops expenses in Q2, raises 2022 profit forecast Mail Online09:24 20-Jul-22
Biogen Beats Q2 Views and Raises Guidance, Analysts Say Focus Remains on Lecanemab Investing.com08:47 20-Jul-22
Biogen Stock Is Falling Despite an Upbeat Outlook. Here's Why. Barron's Online08:25 20-Jul-22
Biogen lifts profit view as MS drugs stay ahead of competition FX Empire08:12 20-Jul-22
Stocks making the biggest moves premarket: Baker Hughes, Biogen, Netflix and more CNBC07:59 20-Jul-22
Biogen's stock is down 2.8% after missing on revenue in the second quarter MarketWatch07:54 20-Jul-22
Biogen Boosts FY22 Outlook As Q2 Results Top Estimates RTT News07:46 20-Jul-22
Biogen Stock Falls Despite Beat-And-Raise Q2 Report Investors Business Daily07:37 20-Jul-22
D.Mass. Limits Plaintiff Experts in False Claims Act Case Lex Blog (Weblog)07:30 20-Jul-22
Netflix, Tesla, Biogen, and More of Wednesday’s Stock Market Movers Barron's Online07:24 20-Jul-22
Biogen profit more than doubles on Samsung Bioepis stake sale Investing.com07:16 20-Jul-22
Biogen Earnings, Revenue Beat in Q2 Investing.com07:16 20-Jul-22
Key Concerns Remain for Biogen Before Q2 Results, Says Analyst TipRanks03:28 20-Jul-22
Genetown's Growing Pains: Eisai Shutters H3 Bio, Biogen Job Cuts have Begun BioSpace10:04 19-Jul-22
Justices Warned That Biogen's Loss Will End Drug Patents Law36021:15 18-Jul-22
Biogen sees more than 330 departures from MA-based sites since last summer ENDPOINTS14:52 18-Jul-22
Drug deals, launches in focus as pharma earnings begin BioPharma Dive12:33 18-Jul-22
Will Biogen (BIIB) Succeed in Beating Q2 Earnings Estimates? Nasdaq12:31 18-Jul-22
Biogen, targeting $1B in savings, employs 300 fewer staffers in Massachusetts than it did in… FiercePharma11:30 18-Jul-22
Polpharma in pole position for biosimilar Tysabri in Europe pharmaphorum07:45 18-Jul-22
Justices Urged To End 'Ominous' Patent Trend In Biogen Case Law36017:25 15-Jul-22
Polpharma Biologics Announces EMA Acceptance for Proposed Biosimilar Natalizumab (Tysabri) European Biotechnology News05:27 15-Jul-22
New Spherix Data in Alzheimer's Disease Reveals High Potential for Emerging Anti-Amyloid… PR Newswire (Press Release)07:05 14-Jul-22
Biogen gains prominent ally in bid for Supreme Court to review Tecfidera patent case FiercePharma14:02 13-Jul-22
No surrender: A group of marquee biotech players bets on the $350M PhIII resurrection story of a heavyweight contender ENDPOINTS07:06 12-Jul-22
Biogen Is Starting To Trend Higher (Technical Analysis) Seeking Alpha15:20 11-Jul-22

      
            
      
    view more headlines
   
      
      
      
5 Aug 10:32
   
About our Biogen News

Biogen is an American multinational biotechnology company that specialises in treatment of neurological diseases.
NewsNow aims to be the world’s most accurate and comprehensive Biogen news aggregator, bringing you the latest headlines automatically and continuously 24/7. N.B. Relevance is automatically assessed so some headlines not qualifying as Biogen news might appear - please feel free to contact us regarding any persistent issues.
Biogen

Latest News

About our Biogen News

Biotech Top Stories

Business Top Stories
